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tumor recurrence and metastasis could be an essential tool to guide the treatment of patients with cholangiocarcinomas.
A multitude of growth factors and their respective signaling pathways have been described to be up-regulated in cholangiocarcinomas. These include the IGF/IGFR, EGF/TGF/EGFR, VEGF/PDGF/VEGFR, Wnt/β-catenin, and the hepatocyte growth factor (HGF)-Met pathway (8, 9) . The receptor tyrosine kinase Met is frequently overexpressed in cholangiocarcinomas, and Met expression has been linked to tumor differentiation and prognosis (10-13). However, the prognostic value of Met seems to differ between ICC and Klatskin tumors, and one study even showed a better patient outcome in case of Met overexpression in ICC (10,12).
Recently, our group discovered a new regulator of the HGF/Met/MAPK pathway, called Metastasis-associated in colon cancer 1 (MACC1). MACC1 was identified by a genome-wide search for differentially expressed genes in human colon cancer tissue, metastases, and normal tissue (14) . The MACC1 gene is located on human chromosome 7 (7p21.1), the same chromosome that contains the genes of Met (7q31.2) and HGF (7q21.1). MACC1 turned out to be a powerful biomarker for the prediction of metachronous distant metastasis as well as survival in colon cancer patients. Based on the expression level of MACC1 mRNA, the negative and positive prediction of distant metastasis was 80% and 74%, respectively (14) .
MACC1 mRNA expression in colon cancer tissue showed a significant correlation with Met mRNA expression. This was further investigated by in vitro studies, which revealed that MACC1 induces proliferation, migration and invasion in different colon carcinoma cell lines. Moreover, MACC1 promoted scattering in the presence of HGF.
MEK inhibitors suppressed cell scattering, and vice versa, active MAPK promoted MACC1 expression. Furthermore, Met proofed to be a transcriptional target of MACC1. Thus, MACC1 is a regulator of the HGF/Met/MAPK signaling pathway (14, 15) . This shows that MACC1 is not only a surrogate marker, but that it is causal for the development of distant metastasis, which makes it a highly interesting therapeutic target beyond its use as a prognostic biomarker (16) .
Here we aimed at determination of the expression levels of MACC1, Met, and HGF in tumor and peritumoral tissue of ICC and Klatskin tumors. We investigate the relationship between MACC1, Met and HGF expression, and analyzed the prognostic significance of MACC1, Met and HGF expression for patient overall survival (OS) and disease-free survival (DFS). To the best of our knowledge, we present the first study Here we show for the first time, that MACC1 mRNA expression predicts OS and DFS in Klatskin tumor patients. This renders it highly interesting as a prognostic tool and makes it a potential therapeutic target for this type of tumor.
Experimental procedures Human subjects
We obtained tumor specimens of 156 patients undergoing surgery between 1998 and 2003 with ICC (n=80) and Klatskin tumors (n=76) from the Department of General-, Visceral-and Transplantation Surgery, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany. Matching peritumoral liver tissue was available in all cases. In addition, we obtained normal bile duct tissue from 3 individuals undergoing surgery for benign liver tumors. All patients were treated by liver 8 resection. None of the patients received (neo-) adjuvant chemotherapy, and none of them had liver transplant. Patients with primary sclerosing cholangitis were not included in this study. The clinical, histopathological, and epidemiological data of the entire group of patients are reported in Supplementary Table 1 . The follow-up period after surgery ranged from 0 days to 4007 days, with a median follow-up of 733 days.
Collection of patient tissue and clinical data was approved by the local ethics committee (Charité Universitätsmedizin Berlin).
Tumor samples
Tissue specimens were collected during surgery, immediately snap frozen in liquid nitrogen and stored at -80°C. The investigators were blinded for patient metadata.
Histology and sample preparation
Serial sections were made of each tumor specimen for hematoxilin eosin (HE) staining, for microdissection with subsequent RNA isolation and for immunohistochemistry. Of each tumor sample, a section was HE stained following routine protocol. All HE stained sections were given to the Department of Pathology, Charité Universitätsmedizin Berlin, and were examined by a certified pathologist.
Tumor diagnosis was confirmed and the respective tumor cell population on the slide was marked as a reference for microdissection. Samples with poor quality (e.g., necrosis) or samples lacking cancerous tissue were omitted from further analyses.
With the exception of tumor diagnosis, the pathologist was blinded for all data, including tumor stage and patient outcome.
RNA extraction
Tumor samples were microdissected and the material was directly immersed into lysis buffer. Total RNA extraction was performed with the GeneMATRIX Universal RNA Purification Kit (Roboklon GmbH, Germany) according to the manufacturer protocol. Total RNA quality was assessed with a Bioanalyzer (2100 Bioanalyzer, RNA Pico Chips, Agilent, CA, USA) and concentration was measured with a NanoDrop spectrophotometer.
qRT-PCR
qRT-PCR was performed using the LightCycler 480 system (Roche Diagnostics). For each sample, a total of 50 ng RNA template was subjected to reverse transcription 
Immunohistochemistry
Immunohistologic staining for MACC1, Met and HGF was carried out for 20 specimens of each tumor entity. The samples were chosen based on normalized MACC1 qRT-PCR expression levels, whereas the specimens with the 10 highest and 10 lowest MACC1 expression levels were chosen. Fresh 5 µm cryosections were air dried for one hour at room temperature, fixed in 10 mM HEPES buffer containing 0,04% glutaraldehyde and 1% glucose, incubated with 0,9% hydrogen peroxide for 30 minutes, permeabilized with PBS containing 0,5% Triton X100 and 2,5% goat serum for 10 minutes, and treated with biotin blocking reagents (DAKO). After blocking with 5% goat serum for 45 minutes, the sections were incubated with the respective primary antibody at 4°C over night (please refer to Supplementary Table 3 for antibodies and dilutions). The sections were incubated with a biotinylated secondary antibody for 30 minutes and treated with a streptavidine peroxidase Analysis was carried out by two independent investigators who were blinded for the study protocol.
Statistical methods
Quantitative variables are expressed as medians. For comparison of groups, Kruskall-Wallis analysis on ranks and Mann-Whitney-U test were used. Inner group comparison was done using the Wilcoxon test.
Main study outcomes were DFS and OS of the patients. DFS was defined as the For the univariate survival analysis, categorical variables were tested using the logrank test, and metric variables were tested with the Cox proportional hazard model. The median expression level of MACC1 in biliary tumors was significantly higher than in the bile duct normal tissue controls, which showed MACC1, Met, and HGF mRNA expression levels comparable to normal liver tissue ( Figure 1C ).
We further investigated the expression levels of MACC1, Met, and HGF in selected histopathological subgroups (tumor size pT, lymph node involvement pN, metastasis pM, tumor grading G, and UICC stage) of each tumor entity. In the Klatskin tumor cohort, MACC1 mRNA expression was significantly higher in patients with a tumor size of pT3 and pT4 than with pT1 and pT2, with 4.14 (pT1+2) vs. 8.03 (pT3+4) MACC1 mRNA expression/% calibrator (p=0.012; Figure 2A ). MACC1 mRNA expression did neither differ significantly between the different UICC stages ( Figure   2B ), nor between the other major clinical features (pN, pM, and G). Met mRNA expression was also significantly higher in patients with a tumor size of pT3 and pT4 (1.27 vs. 2.19 Met mRNA expression/% calibrator; p=0.002) ( Figure 2C ). No significant differences of Met mRNA expressions were found between the UICC stages and other histopathological categories in Klatskin tumor patients. For HGF mRNA expression, no significant differences could be detected for any of the analyzed parameters within the Klatskin tumor cohort.
In the ICC group, MACC1, Met, and HGF mRNA expression did not differ significantly between the histopathologic subgroups with respect to pT, pN, pM, and G category as well as UICC stage.
Survival analysis
MACC1 mRNA expression is a significant and independent prognostic marker for OS in Klatskin tumor patients
Next, we aimed to analyze the prognostic value of MACC1 expression in these tumor entities. ROC analysis was used to determine a cutoff value for OS and DFS. In total 61 out of 76 patients in the Klatskin tumor cohort survived more than 30 days after surgery and had complete clinical follow up. They were considered for survival analysis. In this group, ROC analysis for OS and DFS both yielded a significant area under the curve (AUC) for MACC1 mRNA expression ( Figure 3A) . Thus, the Klatskin tumor cohort was divided in group low and high MACC1 mRNA expression according to the cutoff value calculated by Youden index, which is 8.96 MACC1 mRNA expression/% calibrator (sensitivity 70.8%; specificity 72%) ( Figure 3A) .
Epidemiological, clinical, and histopathological data of Klatskin tumor patients grouped according to MACC1 mRNA expression status are reported in Table 3 .
Univariate survival analysis
The median OS time in the Klatskin tumor cohort was 768 days (CI: 255-1251 days).
Patients with high MACC1 expression had a median OS time of 613 days (CI: 300-926), which was significantly shorter than patients with low MACC1 expression 
Multivariate analysis for survival
We conducted a multivariate analysis to evaluate whether MACC1 mRNA expression is an independent factor for OS in the Klatskin tumor cohort. We used the COX regression model with the stepwise backwards procedure with all variables that had a significance of p<0.1 in the univariate analysis. Independent prognostic significance was detected for MACC1 expression with the ROC derived cutoff (HR 2.777; CI:
1.389-5.555; p=0.004) and lymph node status pN (HR 2.114; CI: 1.114-4.015; p=0.022). Met expression (p=0.601) and tumor size pT (p=0.296) were not significant. Therefore, we found MACC1 mRNA expression to be a strong and independent predictor of OS in Klatskin tumor patients.
MACC1 mRNA expression is a significant prognostic marker for DFS in

Klatskin tumor patients
Patients with a history of tumor recurrence had significantly higher MACC1 mRNA expression than patients without tumor recurrence ( Figure 4A ). Moreover, patients with high MACC1 expression had a significantly shorter median DFS (753 days; CI: 341-1165 days) than patients with low MACC1 expression (>3119 days; CI: n/a; p<0.001) ( Figure 4B ). Met expression and HGF expression did not significantly influence DFS.
MACC1 mRNA expression is not a prognostic marker for survival of ICC patients
In the ICC group, 72 out of 80 patients were eligible for survival analysis. We were not able to generate a significant AUC for MACC1 mRNA expression with ROC analysis for ICC. In ICC, the AUC was 0.263, hence we did not use a ROC-derived cutoff value for survival analysis. 
Discussion
In summary, here we report a first study measuring the expression for MACC1 mRNA, Met mRNA, and HGF mRNA quantitatively in microdissected cholangiocarcinomas. In our study, qRT-PCR was a suitable method to determine MACC1 expression in frozen tumor tissue. Most importantly, we identified MACC1 as a significant and independent prognostic biomarker for OS and DFS in Klatskin tumor patients.
The main goal of our study was to investigate whether MACC1 is of prognostic value in patients with ICC and Klatskin tumors. Additionally, we wanted to investigate the interrelationship between MACC1, Met, and HGF mRNA expression in these tumors and compare the prognostic usefulness between these genes. The scientific basis for this project was a study performed by our group, which identified MACC1 as a key regulator of the HGF-Met signaling pathway and demonstrated its ability to predict colon cancer metastasis not only when measured in solid tumors, but also when detected in human plasma (14, 17) . Therefore, we determined MACC1, Met, and HGF mRNA expression levels quantitatively using real-time RT-PCR in microdissected tumor tissue.
We found highly elevated MACC1 mRNA expression values in intrahepatic and hilar cholangiocarcinoma. MACC1 mRNA expression was approximately 10 times higher in intrahepatic cholangiocarcinoma and Klatskin tumors than in peritumorous normal liver tissue. Gene expression profliling in ICCs also showed elevated MACC1 expression levels (18) . While the MACC1 expression in the Klatskin tumor cohort did not differ between the UICC tumor stages, we found significantly higher MACC1 expression values in patients with a tumor size of pT3 and pT4 compared to pT1 and pT2. In addition, patients with a history of tumor recurrence had a significantly higher MACC1 expression than those without tumor recurrence. Although all Klatskin tumor patients with a poorly differentiated tumor (G3) were found in the high MACC1 mRNA expression group (Table 3) , we found no significant difference in MACC1 mRNA expression between the different tumor grading categories. This finding is somewhat similar to the results reported on MACC1 expression in colorectal carcinoma, where MACC1 expression did not differ significantly between the different UICC stages but was significantly higher expressed in patients with metachronous metastasis (14, 19) .
Performing survival analysis, we found patients with low MACC1 expression having a highly significantly longer DFS time and a significantly longer OS time. To the best of our knowledge, this is the first report of a prognostic biomarker for Klatskin tumor patients.
It might seem controversial that, given the fact that MACC1 expression was elevated Currently, the only curative therapeutic option available for Klatskin tumors is radical surgery with complete tumor removal (27) (28) (29) . However, surgical resectability is often not given, and liver transplantation might seem a rational therapeutic approach to achieve complete tumor removal. Interestingly, in our patient cohort the only independent prognostic marker besides MACC1 expression was the lymph node status, which was also of prognostic significance in transplant trials for Klatskin tumors (7, 30, 31) The possibility of tumor recurrence is the major drawback for liver transplantation, and given the lack of biomarkers for the prediction of tumor 
Conclusion
In summary, our study identifies MACC1 as a highly prognostic biomarker for OS and 
